Want to see JNJ full AI Analyst Report?

Johnson & Johnson (JNJ) Price & Analysis

28,639 Followers

JNJ Stock Chart & Stats

$273.14

$4.13(1.59%)

At close: Jul 24 4:00 PM EDT

$273.14

$4.13(1.59%)

Day’s Range― - ―

52-Week Range$184.66 - $281.07

Previous CloseN/A

Volume6.35M

Average Volume (3M)7.23M

Market Cap

$621.22B

Enterprise Value$691.53B

Total Cash (Recent Filing)$20.76B

Total Debt (Recent Filing)$49.04B

Price to Earnings (P/E)39.1

Beta>-0.01

Next Earnings

Jan 26, 2027

EPS Estimate

2.9

Next Dividend Ex-DateN/A

Dividend Yield2.05%

Share Statistics

EPS (TTM)8.65

Shares Outstanding2,409,898,700

10 Day Avg. Volume7,985,482

30 Day Avg. Volume7,234,431

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)6.18

Price to Sales (P/S)5.35

P/FCF Ratio25.59

Enterprise Value/Market Cap1.11

Enterprise Value/Revenue7.06

Enterprise Value/Gross Profit10.40

Enterprise Value/Ebitda20.50

Forecast

1Y Price Target

$278.78

Price Target Upside2.06% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering19

EPS Forecast (FY)11.11

Revenue Forecast (FY)$101.21B

Bulls Say, Bears Say

Bulls Say

Innovative Medicine GrowthStrong growth across multiple Innovative Medicine brands indicates broad-based portfolio momentum rather than dependence on one product. Continued adoption in oncology, immunology and neuroscience can support durable revenue expansion and strengthen J&J’s market position.

Conservative Balance SheetLow leverage gives Johnson & Johnson financial flexibility to fund research, acquisitions, dividends and litigation obligations without relying heavily on debt. This conservative capital structure also improves resilience if healthcare reimbursement or product trends weaken.

Innovation And Pipeline ExpansionInvestment in next-generation oncology technology expands J&J’s potential pipeline beyond current commercial franchises. Although near-term earnings are diluted, the added platforms can improve long-term growth prospects and support leadership in difficult cancer indications.

Bears Say

Biosimilar PressureBiosimilar competition creates a durable erosion risk for STELARA revenue as treatment markets shift toward lower-cost alternatives and newer therapies. This pressure can offset growth from newer launches and makes portfolio replacement execution important.

Margin CompressionThe sharp margin decline shows that strong sales growth is not fully converting into operating profit. Product mix, amortization, research spending and transaction costs may continue limiting earnings conversion and reduce the durability of near-term profit expansion.

Talc Litigation BurdenThe proposed settlement represents a substantial financial obligation and remains conditional on participation by at least 95% of claimants. Litigation costs can pressure cash allocation, create earnings volatility and distract management from core healthcare investment priorities.

Johnson & Johnson News

Johnson & Johnson reports real-world VARIPULSE Pro platform data

Johnson & Johnson announced new data from the late-breaking VARIPURE and Omny-IRE studies presented at the Asia Pacific...

1h ago

JNJ

Johnson & Johnson downgraded to Hold from Buy at Erste Group

Erste Group downgraded Johnson & Johnson to Hold from Buy. On a sector-by-sector basis, the stock is trading...

1d ago

JNJ

Johnson & Johnson announces U.S. launch of Shockwave C2 Aero Fly catheter

Johnson & Johnson announced the U.S. launch of its Shockwave C2 Aero Fly Coronary IVL Catheter designed to...

2d ago

JNJ

Johnson & Johnson (JNJ) Has Improved, but I’m Holding Off after the Rally

Johnson & Johnson’s ($JNJ) rally has me holding off, despite an improving business. The global healthcare products maker...

3d ago

JNJ

Johnson & Johnson reports results from Phase 3 FUZION study

Johnson & Johnson announced one-year results from the Phase 3 FUZION study showing TREMFYA, or guselkumab, maintained or...

3d ago

JNJ

Leaning Into Energy Stocks as Midterm Elections Draw Near

I don’t care to make predictions about elections. Even professional pollsters have difficulty with that task. I will...

6d ago

APA

COP

Johnson & Johnson price target raised to $287 from $275 at Wells Fargo

Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Johnson & Johnson (JNJ) to $287 from...

6d ago

JNJ

KVUE

Johnson & Johnson price target lowered to $292 from $294 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Johnson & Johnson to $292 from $294 and keeps an...

7d ago

JNJ

Johnson & Johnson price target lowered to $280 from $290 at RBC Capital

RBC Capital lowered the firm’s price target on Johnson & Johnson to $280 from $290 and keeps an...

8d ago

JNJ

Johnson & Johnson price target lowered to $272 from $276 at Leerink

Leerink lowered the firm’s price target on Johnson & Johnson to $272 from $276 and keeps an Outperform...

8d ago

JNJ

Boston Scientific price target lowered to $51 from $57 at Truist

Truist lowered the firm’s price target on Boston Scientific (BSX) to $51 from $57 and keeps a Buy...

8d ago

BSX

JNJ

Johnson & Johnson price target lowered to $275 from $282 at BofA

BofA analyst Jason Gerberry lowered the firm’s price target on Johnson & Johnson to $275 from $282 and...

8d ago

JNJ

3 ETFs Tipped for 10% or More Gains by AI Analyst

Exchange-traded funds (ETFs) offer a key way to enter financial markets. For investors looking for a starting point...

9d ago

JNJ

Why SpaceX and J&J Stocks Are Falling Today — and What Wall Street Sees Next

Two Wall Street heavyweights are having a painful Tuesday, although their troubles have little in common. SpaceX (NASDAQ:SPCX)...

9d ago

JNJ

SPCX

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?

Johnson & Johnson lowest stock price was $184.66 and its highest was $281.07 in the past 12 months.

What is Johnson & Johnson’s market cap?

Johnson & Johnson’s market cap is $621.22B.

When is Johnson & Johnson’s upcoming earnings report date?

Johnson & Johnson’s upcoming earnings report date is Jan 26, 2027 which is in 96 days.

How were Johnson & Johnson’s earnings last quarter?

Johnson & Johnson released its earnings results on Oct 13, 2026. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.522 by $0.068.

Is Johnson & Johnson overvalued?

According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson pay dividends?

Johnson & Johnson pays a Quarterly dividend of $1.34 which represents an annual dividend yield of 2.05%. See more information on Johnson & Johnson dividends here

What is Johnson & Johnson’s EPS estimate?

Johnson & Johnson’s EPS estimate is 2.9.

How many shares outstanding does Johnson & Johnson have?

Johnson & Johnson has 2,409,898,700 shares outstanding.

What happened to Johnson & Johnson’s price movement after its last earnings report?

Johnson & Johnson reported an EPS of $2.59 in its last earnings report, beating expectations of $2.522. Following the earnings report the stock price went down -5.733%.

Which hedge fund is a major shareholder of Johnson & Johnson?

Currently, no hedge funds are holding shares in JNJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Johnson & Johnson Stock Smart Score

Outperform

Fundamentals

Return on Equity

19.55%

Trailing 12-Months

Asset Growth

2.39%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson (JNJ) Earnings & Revenues

Historic Earnings Reports

JNJ Company Deck

JNJ Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call was predominantly positive. Johnson & Johnson reported 6% operational sales growth, strong momentum in Innovative Medicine, significant growth from key oncology, immunology, and neuroscience brands, progress in MedTech innovation, strong cash generation, and raised 2026 guidance. These positives were partly offset by a MedTech performance shortfall, declines in Abiomed, surgery, and STELARA, lower adjusted EPS and margins, and substantial talc litigation and transaction-related charges. Management nevertheless expressed confidence in improving MedTech performance, finishing 2026 strongly, and achieving double-digit growth by the end of the decade.View all JNJ earnings summaries

JNJ Sales Breakdown

64.12% Innovative Medicine

35.88% MedTech

JNJ Stock 12 Month Forecast

Average Price Target

$278.78

▲(2.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"109":"$109","162":"$162","215":"$215","268":"$268","321":"$321"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":320,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$320.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":278.77777777777777,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$278.78</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[109,162,215,268,321],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,258.66,263.3784615384616,268.0969230769231,272.81538461538463,277.5338461538462,282.2523076923077,286.97076923076924,291.6892307692308,296.4076923076923,301.12615384615384,305.8446153846154,310.5630769230769,315.28153846153845,{"y":320,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,258.66,260.2075213675214,261.75504273504276,263.30256410256413,264.8500854700855,266.3976068376069,267.94512820512824,269.49264957264955,271.0401709401709,272.5876923076923,274.13521367521366,275.68273504273503,277.2302564102564,{"y":278.77777777777777,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,258.66,247.22461538461542,235.78923076923078,224.35384615384618,212.91846153846154,201.48307692307694,190.04769230769233,178.6123076923077,167.1769230769231,155.74153846153848,144.30615384615385,132.87076923076924,121.43538461538463,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":181.949,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.707,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.089,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.674,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.097,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.925,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":241.532,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":224.782,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.413,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.733,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.091,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.19,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":258.66,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >